ADC Development Services Targeting LY6E

Traditional chemotherapies are limited by a narrow therapeutic index resulting in suboptimal exposure of the tumor to the drug and acquired tumor resistance. An alternative to overcome this is therapy based on antibody-drug conjugates (ADCs), which can achieve greater potency via target-specific delivery of highly potent cytotoxic agents. Research results disclosure lymphocyte antigen 6 complex locus E (LY6E) can serve as a highly promising therapy target for a variety of solid tumor types including non-small cell lung cancer (NSCLC) and breast cancer. As a expert in ADC development, Creative Biolabs offers one-stop-shop ADC contract services targeting LY6E for our global clients.

Introduction of LY6E

LY6E, an IFN-inducible glycosylphosphatidylinositol (GPI)-linked cell membrane protein, is significantly over-expressed and amplified in a wide array of different human solid tumors, including ovarian, pancreatic, lung, gastric, and breast cancer. LY6E has been shown to modulate viral infection in a cell type-dependent manner. Its broad expression pattern across a wide range of different human cancers has aroused wide attention of the industry in exploring the therapeutic potential.

Fig.1 LY6E gene expression profile: Each dot represents LY6E gene expression in normal (black), cancer (red), and diseased (blue) human tissues. (Asundi, 2015)

Anti-LY6E ADC in NSCLC and Breast Cancer

Increased expression of LY6E in human NSCLC and breast cancer correlates with poor overall survival and poor therapeutic outcomes. Scientists also found an overall trend toward increased LY6E gene copy number correlating to increased LY6E cell-surface expression and enhanced in vitro anti-LY6E ADC activity in breast and lung cancer cell lines. To pursue LY6E as an ADC target, many attempts have been made to develop anti-LY6E ADC. Characterization of the endocytic pathways for LY6E revealed that the LY6E-specific antibody is internalized into cells leading to lysosomal accumulation. Besides, an anti-LY6E monomethylauristatin E (MMAE) ADC was demonstrated to have potent efficacy both in vitro and in vivo in different LY6E-expressing tumor models, including patient-derived xenografts (PDX) with heterogeneous expression. Data suggests that anti-LY6E ADC has great potential as a therapeutic agent for many cancers of unmet medical need in the clinical setting.

ADC Development Services Targeting LY6E

Creative Biolabs possesses unique ADC Antibody Screening platform to screen “internalizing” antibodies which is of highly importance in ADC assembly. Our Antibody Design and Conjugation platform has been tested by numerous successful ADC projects and our perfect DrugLnk™ Custom Synthesis platform also supplies customary synthesis of individual toxins module, linker module and drug-linker complexes. Moreover, ADC in vivo Analysis and ADC in vitro Analysis are also available in Creative Biolabs. With more than ten years' expertise in antibody production and bio-conjugation, we are confident to provide the most comprehensive anti-LY6E ADC design and production service package. Please contact us for more information and a detailed quote.

Reference

1. Asundi, J.; et al. An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies. Clinical Cancer Research. 2015, 21(14): 3252-3262.

For Research Use Only. NOT FOR CLINICAL USE.